

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**CanSino Biologics Inc.**  
**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6185)**

**RESIGNATION OF DIRECTOR  
AND  
PROPOSED APPOINTMENT OF DIRECTOR**

**RESIGNATION OF DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of CanSino Biologics Inc. (the “**Company**”) hereby announces that, Ms. Nisa Bernice Wing-Yu LEUNG (“**Ms. Leung**”) has tendered her resignation as a non-executive Director of the Company and a member of the nomination committee under the Board (the “**Nomination Committee**”) due to her personal work arrangements, with effect from May 30, 2024.

Ms. Leung has confirmed that she has no disagreement with the Company and the Board of Directors, and there are no other matters relating to her resignation that need to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) and the shareholders of the Company (the “**Shareholders**”).

The Board would like to take this opportunity to thank Ms. Leung for her valuable contributions to the Group during her tenure of office.

**PROPOSED APPOINTMENT OF DIRECTOR**

The Board of the Company announces that Mr. Chi Shing LI (李志成) (“**Mr. Li**”) is nominated as a candidate for non-executive Director of the third session of the Board and member of the Nomination Committee. The proposed appointment of Mr. Li will be submitted to the annual general meeting for consideration and approval.

Biographical details of Mr. Li are set out as follows:

**Chi Shing LI (李志成)**, aged 67, joined Qiming Venture Partners in 2024 and currently serves as a venture partner. He previously worked for CSL Behring Asia Pacific Limited, where he served as a senior vice president and general manager from 2022 to 2024, and vice president and general manager from 2015 to 2022. He was the chief executive officer of Quality Healthcare Medical Services Limited from 2012 to 2015. Prior to that, he was the vice president of Asia Pacific and International region at Cephalon Inc. successively. He spent eight years, from 1997 to 2005, with Merck, where he served as the regional director of Asia North, with responsibility for leading operations in China, Hong Kong, Korea and Taiwan, vice president for Asia as well as president for China and Hong Kong. He served as the commercial director of Abbott Laboratories Taiwan Limited in 1996. From 1980 to 1995, he held various positions at Eli Lilly and Company including Human Resources and training manager of the South East Asia region and director of pharmaceutical marketing in Taiwan and China.

Mr. Li has been a senior advisor in TE Healthcare Advisory Pte Ltd and a director of Hong Kong Integrated Oncology Centre since 2022. He was an independent non-executive director of JW (Cayman) Therapeutics Co. Ltd (a company listed on the Hong Kong Stock Exchange, stock code: 2126) from 2020 to 2022, chairman of the board of CSL Behring Asia Pacific Limited from 2015 to 2023. He was a member of the Steering Committee on Electronic Health Record Sharing established by the Secretary for Food and Health of Hong Kong and facilitated the commencement of the operation of the record sharing system from 2013 to 2015. He was member of professional services advisory committee of Hong Kong Trade Development Council from 2012 to 2015.

Mr. Li obtained his diploma in chemistry from Hong Kong Baptist University in November 1980 in Hong Kong. He achieved a master of business administration degree from the University of East Asia in Macau in September 1986. He achieved his post-graduate diploma in management consulting from the University of Hong Kong in October 2006 in Hong Kong.

Mr. Li meets the qualification requirements to serve as a director as stipulated in relevant laws, regulations and the articles of association of the Company (the “**Articles of Association**”). Mr. Li’s term of office shall commence from the date of approval at the annual general meeting until the expiry of the term of the third session of the Board. Pursuant to the Articles of Association, he shall be eligible for re-election upon the expiry of his term of office. The Company will enter into a service contract with Mr. Li upon approval at the annual general meeting. As a non-executive Director, Mr. Li will not receive any director’s fee or remuneration from the Company.

As of the date of this announcement and as far as the Board is aware, save as disclosed above, Mr. Li has confirmed that (i) he does not hold directorship in other listed companies for the past three years, has no any other major appointment and professional qualifications nor any position in the Group; (ii) he does not have any relationship with any Directors, supervisors, senior management or substantial or controlling Shareholders; and (iii) he does not have any interest in the shares of the Company or its associated corporation within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Mr. Li has not been subject to any penalty or punishment imposed by the China Securities Regulatory Commission or any other relevant authorities or stock exchanges.

Mr. Li has confirmed that there is no other matter relating to his appointment that needs to be brought to the attention of the Shareholders, and there is no other information that needs to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, May 31, 2024

*As of the date of this announcement, the Board comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, and Mr. Shuifa GUI, Mr. Jianzhong LIU and Mr. Yiu Leung Andy CHEUNG as independent non-executive Directors.*